1Dialysis Access Institute, John Ross, MD, Orangeburg, SC (enrolling site in Lutonix DCB IDE study)
2Treated cephalic arch stenoses in 53% of enrolled patients
3Excluded patients with residual stenosis ≥30% following PTA to open the stenosis (e.g., vessel prep); treated cephalic arch stenoses in 19% of enrolled patients